{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dextrose+20+%25+in+Water", "query": { "intervention": "Dextrose 20 % in Water" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 60, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dextrose+20+%25+in+Water&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T15:29:14.919Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01814046", "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Ocular Melanoma", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Young Tumor Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2013-03-01", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2018-10-11", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01814046" }, { "nct_id": "NCT01681095", "title": "Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronary Artery Disease", "Myocardial Ischemia", "Coronary Disease", "Heart Diseases", "Valvular Heart Disease" ], "interventions": [ { "name": "Custodiol HTK", "type": "DRUG" }, { "name": "Cold Blood Cardioplegia", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marc Sakwa, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2012-08", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2019-08-06", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "Royal Oak, Michigan", "locations": [ { "city": "Royal Oak", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01681095" }, { "nct_id": "NCT07403604", "title": "Effect of Insulin Lowering on Lipogenesis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hyperinsulinemia", "Insulin Resistance", "Non-Alcoholic Fatty Liver Disease", "Prediabetic State", "Obesity" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Diazoxide Oral Suspension, 2 mg per kg per dose", "type": "DRUG" }, { "name": "Deuterated water (2H2O/D2O), 70%", "type": "DRUG" }, { "name": "Insulin Suppression Test (IST)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2026-07-01", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07403604" }, { "nct_id": "NCT04291508", "title": "Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Respiratory Distress Syndrome", "Critical Illness", "Respiratory Failure", "Sepsis" ], "interventions": [ { "name": "Intravenous Acetaminophen (room temperature)", "type": "DRUG" }, { "name": "Intravenous Vitamin C (refrigerated)", "type": "DRUG" }, { "name": "5% Dextrose (room temperature)", "type": "DRUG" }, { "name": "5% Dextrose refrigerated", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 488, "start_date": "2021-10-13", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04291508" }, { "nct_id": "NCT01468818", "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Skin Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Young Tumor Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 18, "start_date": "2011-09", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-06-27", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01468818" }, { "nct_id": "NCT02931578", "title": "Glycemic Index of Commonly Consumed Sweeteners", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Glucose100", "type": "OTHER" }, { "name": "Glucose50", "type": "OTHER" }, { "name": "Glucose42", "type": "OTHER" }, { "name": "Oral Glucose Tolerance Test", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 12, "start_date": "2016-10", "completion_date": "2018-11", "has_results": false, "last_update_posted_date": "2019-11-26", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02931578" }, { "nct_id": "NCT02062359", "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Metastatic Melanoma" ], "interventions": [ { "name": "Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2014-02", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2016-06-24", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02062359" }, { "nct_id": "NCT00787761", "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic HSCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787761" }, { "nct_id": "NCT00930202", "title": "Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Severe Traumatic Brain Injury" ], "interventions": [ { "name": "Conivaptan (Vaprisol)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2009-08", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2010-09-10", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00930202" }, { "nct_id": "NCT03559101", "title": "Effects of Amino Acid/Electrolyte-based Beverages on Hydration Status", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dehydration" ], "interventions": [ { "name": "Distilled water", "type": "OTHER" }, { "name": "Medical Food 1", "type": "OTHER" }, { "name": "Medical Food 2", "type": "OTHER" }, { "name": "Pedialyte", "type": "OTHER" }, { "name": "Gatorade", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "W. Larry Kenney", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 32, "start_date": "2017-05-25", "completion_date": "2017-12-18", "has_results": false, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-09-24T15:29:14.919Z", "location_count": 1, "location_summary": "University Park, Pennsylvania", "locations": [ { "city": "University Park", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03559101" } ] }